LTRN 주식 개요 임상 단계의 생명공학 회사인 Lantern Pharma는 인공지능, 머신러닝, 게놈 데이터에 집중하여 신약 개발 프로세스를 간소화하는 데 주력하고 있습니다. 자세한 내용
위험 분석 + 1 더 많은 위험
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Lantern Pharma 과거 주가 현재 주가 US$4.48 52주 최고치 US$11.99 52주 최저치 US$2.79 베타 1.53 1개월 변경 48.34% 3개월 변경 사항 29.86% 1년 변경 사항 6.39% 3년 변화 -28.21% 5년 변화 n/a IPO 이후 변화 -70.03%
최근 뉴스 및 업데이트
Lantern Pharma Inc. Announces First Patient Enrolled in Taiwan for Phase 2 Harmonic Clinical Trial of LP-300 in never-Smoker NSCLC Patients Dec 10
Lantern Pharma Inc.'S Investigational Drug-Candidate, Lp-184, Receives Second Fast Track Designation from Fda for Treatment of Triple Negative Breast Cancer Dec 04
Lantern Pharma Inc. Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic Clinical Trial of LP-300 in Never-Smoker NSCLC Patients Nov 20
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? Nov 05
Lantern Pharma Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Lantern Pharma's Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation in Glioblastoma from the Fda Oct 16 더 많은 업데이트 보기
Lantern Pharma Inc. Announces First Patient Enrolled in Taiwan for Phase 2 Harmonic Clinical Trial of LP-300 in never-Smoker NSCLC Patients Dec 10
Lantern Pharma Inc.'S Investigational Drug-Candidate, Lp-184, Receives Second Fast Track Designation from Fda for Treatment of Triple Negative Breast Cancer Dec 04
Lantern Pharma Inc. Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic Clinical Trial of LP-300 in Never-Smoker NSCLC Patients Nov 20
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? Nov 05
Lantern Pharma Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Lantern Pharma's Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation in Glioblastoma from the Fda Oct 16
Lantern Pharma Highlights Promising Preclinical Results of LP-184'S Synergy with Checkpoint Inhibitors & Sensitizing Tumors That Are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson At Immuno-Oncology Summit 2024 Aug 08
Lantern Pharma Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for Use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 Jul 11
Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell 3000E Value Index Jul 03
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans Jun 12
Lantern Pharma Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Lantern Pharma Inc., Annual General Meeting, Jun 13, 2024 May 01
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan Apr 23
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284 Mar 15
Lantern Pharma Inc. to Report Q4, 2023 Results on Mar 18, 2024 Mar 12
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR Mar 06
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely Feb 28
Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers Feb 15
New minor risk - Share price stability Nov 10
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate Nov 06
Lantern Pharma Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 02
Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company Oct 22
Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma Oct 05
Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors Sep 26
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas Sep 19
Lantern Pharma Inc. to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting Sep 01
Lantern Pharma Inc. Expands AI Capabilities of RADR(R) Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors Aug 29
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans Jul 20
Oncotarget Publishes New Data by Lantern Pharma Further Supporting Clinical Advancement of LP-284, A Novel Synthetic Lethal Drug Candidate for Non-Hodgkin's Lymphomas Jun 27
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors Jun 13
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University Jun 09
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely Apr 04
Lantern Pharma Inc. Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates Feb 16
Lantern Pharma Inc. Receives Pre-IND Feedback from the FDA Jan 18
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation Dec 19
Lantern Pharma Inc. Announces Positive New Data for Its Drug Candidate LP-284 for Mantle Cell Lymphoma Dec 17
Lantern Pharma Inc. Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS) Dec 14
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate Lp-184 for Glioblastoma Nov 23
Price target decreased to US$18.50 Nov 16
Lantern Pharma Inc. to Report Q3, 2022 Results on Nov 07, 2022 Nov 01
Lantern Pharma Inc. to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting Sep 24
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely Sep 02
Lantern Pharma Receives Food and Drug Administration Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer Jul 15
Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer Jul 14
Price target decreased to US$26.00 May 24
Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth May 20
Lantern Pharma Inc. Announces Leslie W. Kreis, Jr. Not to Stand for Reelection as A Director Apr 27
Lantern Pharma Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 23
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation Feb 02
Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for Lp-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor Jan 25
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology Dec 15
Lantern Pharma Inc. (NasdaqCM:LTRN) announces an Equity Buyback for $7 million worth of its shares. Nov 24
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely Oct 13
Price target increased to US$29.50 Sep 19
Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer Aug 24
Lantern Pharma: Drug Recycling With AI Jun 08
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate May 05
Lantern Pharma reports Q1 results May 03
Lantern Pharma Announces That RADR® Has Exceeded 4.6 Billion Datapoints Apr 30
Lantern Pharma Inc. Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget Apr 27
Lantern Pharma Inc. Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties Mar 18
Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like Feb 19
Lantern Pharma Inc. has completed a Follow-on Equity Offering in the amount of $60.00001 million. Jan 15
New 90-day low: US$14.51 Jan 15 Lantern Pharma Inc. and AF Chemicals, LLC Enter into Second Addendum to Technology License Agreement
Lantern Pharma Announces Launch of Antibody Drug Conjugate (Adc) Program to Target Solid Tumors & Blood Cancers Through Agreement with Califia Pharma Jan 06
Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma Jan 04
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares? Dec 28
Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma Dec 19
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers Dec 17
Lantern: Early Stage 'Smart Drug' Discovery Company Nov 25
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, A Next-Generation, Targeted DNA-Damaging Agent Oct 06
New 90-day high: US$21.25 Sep 29
Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer Sep 23
New 90-day high - US$19.24 Sep 12 주주 수익률 LTRN US Biotechs US 마켓 7D 26.9% 2.0% 2.4% 1Y 6.4% -4.1% 25.0%
전체 주주 수익률 보기
수익률 대 산업: LTRN 지난 1년 동안 -4.1 %를 반환한 US Biotechs 산업을 초과했습니다.
수익률 대 시장: LTRN 지난 1년 동안 25 %를 반환한 US 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is LTRN's price volatile compared to industry and market? LTRN volatility LTRN Average Weekly Movement 13.9% Biotechs Industry Average Movement 11.3% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.3%
안정적인 주가: LTRN 의 주가는 지난 3개월 동안 US 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: LTRN 의 주간 변동성 ( 14% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.
회사 소개 임상 단계의 생명공학 회사인 랜턴 파마는 인공지능, 머신러닝, 게놈 데이터에 집중하여 신약 개발 프로세스를 간소화하는 데 주력하고 있습니다. 제품 파이프라인은 비흡연자 비소세포폐암 선암 병용요법 임상 2상 중인 LP-300, 췌장암, 유방암, 방광암, 폐암 등 고형암과 교모세포종 및 기타 중추신경계 암 치료를 위한 임상 1상 중인 LP-184, 맨틀세포 림프종 및 이중 타격 림프종을 포함한 비호지킨 림프종 치료를 위한 임상 1상 중인 LP-284로 구성되어 있습니다. 교모세포종, 뇌전이, 비정형 횡문근종양, 소아 희귀질환 지정을 위한 전임상 개발 중인 STAR-001을 개발 중입니다.
자세히 보기 Lantern Pharma Inc. 기본 사항 요약 Lantern Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요? LTRN 기본 통계 시가총액 US$43.89m 수익(TTM ) -US$19.09m 수익(TTM ) n/a
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) LTRN 손익 계산서(TTM ) 수익 US$0 수익 비용 US$0 총 이익 US$0 기타 비용 US$19.09m 수익 -US$19.09m
주당 순이익(EPS) -1.77 총 마진 0.00% 순이익 마진 0.00% 부채/자본 비율 0%
LTRN 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/22 04:34 장 마감 주가 2025/01/22 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Lantern Pharma Inc. 2 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Ashok Kumar ThinkEquity LLC John Vandermosten Zacks Small-Cap Research
0 더 많은 분석가 보기 
